Tirzepatide is a once-weekly subcutaneous injection of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved in the US and EU for the treatment of T2D and obesity. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.